Physician profile
Phyllis M Trust
NPI 1194085811
$2,780.51
in general payments reported to CMS, 2019-2025
25 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $194 · 2021: $62.89 · 2022: $356 · 2023: $629 · 2024: $492 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $641.59 | 2022-2025 | |
| Dexcom, INC. | $527.84 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $413.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $153.14 | 2021-2025 | Minimed 780g, Simplera Sensor |
| Insulet Corporation | $118.07 | 2019-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $106.46 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $100.22 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $79.13 | 2020-2025 | Botox, Synthroid |
| Lilly USA, LLC | $78.15 | 2019-2024 | Mounjaro |
| Ascensia Diabetes Care US INC. | $67.12 | 2024 | |
| Abbott Laboratories | $65.14 | 2023-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $60.90 | 2022-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $49.69 | 2022-2025 | |
| Amgen INC. | $43.05 | 2023-2025 | Repatha, Repatha |
| Antares Pharma, INC. | $34.57 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $33.94 | 2019 | |
| Ibsa Pharma INC. | $32.99 | 2023-2024 | Tirosint, Licart, Licart |
| Intrabio INC | $25.32 | 2025 | Aqneursa |
| Kyowa Kirin, INC. | $24.59 | 2025 | |
| Beta Bionics, INC. | $24.22 | 2024 | Ilet Bionic Pancreas |
| Pfizer INC. | $22.06 | 2023 | |
| Sanofi-Aventis U.S. LLC | $21.84 | 2024 | |
| Ascendis Pharma Endocrinology INC | $21.12 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $18.07 | 2023 | Farxiga |
| Recordati_rare_diseases_inc. | $17.62 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Trust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.